Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia

Ivosidenib is an oral inhibitor of the mutant isocitrate dehydrogenase 1 (IDH1) enzyme, approved for treatment of IDH1-mutant (mIDH1) acute myeloid leukemia (AML). Preclinical work suggested that addition of azacitidine to ivosidenib enhances mIDH1 inhibition–related differentiation and apoptosis. P...

Descripción completa

Detalles Bibliográficos
Autores principales: DiNardo, Courtney D., Stein, Anthony S., Stein, Eytan M., Fathi, Amir T., Frankfurt, Olga, Schuh, Andre C., Döhner, Hartmut, Martinelli, Giovanni, Patel, Prapti A., Raffoux, Emmanuel, Tan, Peter, Zeidan, Amer M., de Botton, Stéphane, Kantarjian, Hagop M., Stone, Richard M., Frattini, Mark G., Lersch, Frederik, Gong, Jing, Gianolio, Diego A., Zhang, Vickie, Franovic, Aleksandra, Fan, Bin, Goldwasser, Meredith, Daigle, Scott, Choe, Sung, Wu, Bin, Winkler, Thomas, Vyas, Paresh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7771719/
https://www.ncbi.nlm.nih.gov/pubmed/33119479
http://dx.doi.org/10.1200/JCO.20.01632

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7771719/
https://www.ncbi.nlm.nih.gov/pubmed/33119479
http://dx.doi.org/10.1200/JCO.20.01632

Ejemplares similares